drugset / Trial / NCT06240351
A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)
Phase 4
Active not recruiting
15 enrolled
University of Alabama at Birmingham
Eli Lilly and Company · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to evaluate the safety and efficacy of Baricitinib in the treatment of frontal fibrosing alopecia (FFA).
Timeline
- Start
- 2024-04-22
- Primary completion
- 2026-10-31
- Completion
- 2027-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Baricitinib | Small molecule | 4 mg | Oral |